Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Aim(s): This is an open-label, single-arm study to further assess the efficacy and safety of sulfatinib in pts with advanced grade 1 or 2 NETs.
Materials and methods: Sulfatinib was orally given 300 mg, qd, until disease progression or unacceptable toxicity. Tumor responses were assessed using RECIST v 1.1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
, Li J
, Bai C M
, Xu N
, Zhou Z W
, Li Z P
, Zhou C C
, Wang W
, Li J
, Qi C
, Hua Y
, Su W G
To read results and conclusion, please login ...
Further abstracts you may be interested in